Inhaled Insulin

Afrezza, an ultra rapid-acting inhaled insulin, offers an alternative to injections for mealtime glucose management. It starts working in 12 minutes and works well for some, but not for all people with diabetes. 

There have never been more options for tracking blood sugar and delivering insulin. Depending on insurance, cost, and availability, people with diabetes may be able to try different CGM, insulin pumps, and AID systems and figure out what works for them.

Inhalable Afrezza is the fastest-acting insulin available. It eliminates the need for pre-bolusing and can reduce meal-time spikes and low blood sugar. Here are tips and expert guidance on using inhaled insulin.  

After the rapid-acting inhaled insulin Afrezza launched this February, we have been very eager to learn more about how this new product impacts patients’ day-to-day diabetes management. We recently spoke with Ana Ortiz (a type 1 patient) and Bill Kinder (a type 2 patient), two Afrezza users with very different backgrounds...

New trial testing the inhaled, ultra-rapid insulin in 4-17 year olds.

Goal to maintain access to therapy over next six months. What challenges have been seen to date?